Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
McKesson
Mallinckrodt
Merck

Last Updated: January 30, 2023

Vorapaxar sulfate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for vorapaxar sulfate and what is the scope of patent protection?

Vorapaxar sulfate is the generic ingredient in one branded drug marketed by Xspire Pharma and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vorapaxar sulfate has one hundred and sixty-four patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for vorapaxar sulfate
International Patents:164
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 41
Clinical Trials: 1
Patent Applications: 19
DailyMed Link:vorapaxar sulfate at DailyMed
Recent Clinical Trials for vorapaxar sulfate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 2
Matthew MellPhase 2
Ken MahaffeyPhase 2

See all vorapaxar sulfate clinical trials

Pharmacology for vorapaxar sulfate

US Patents and Regulatory Information for vorapaxar sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for vorapaxar sulfate

Country Patent Number Title Estimated Expiration
Peru 20050471 ANTAGONISTAS DEL RECEPTOR DE TROMBINA See Plans and Pricing
Russian Federation 2355689 КРИСТАЛЛИЧЕСКАЯ ПОЛИМОРФНАЯ ФОРМА БИСУЛЬФАТНОЙ СОЛИ АНТАГОНИСТА ТРОМБИНОВОГО РЕЦЕПТОРА (CRYSTALLINE POLYMORPHOUS FORM OF THROMBIN RECEPTOR ANTAGONIST BISULFATE) See Plans and Pricing
Japan 2007510750 See Plans and Pricing
Australia 6690001 Thrombin receptor antagonists See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for vorapaxar sulfate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 2015C/037 Belgium See Plans and Pricing PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
1495018 122015000053 Germany See Plans and Pricing PRODUCT NAME: VORAPAXAR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018 PA2015027 Lithuania See Plans and Pricing PRODUCT NAME: VORAPAXARUM; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018 C01495018/01 Switzerland See Plans and Pricing PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65803 19.09.2016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Mallinckrodt
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.